OnKure Therapeutics Reports First Quarter 2026 Financial Results

-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα  pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα  pan-mutant programs into clinical development in 2027 -- $192 million cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

GlobeNewsWire • May 5, 2026

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million.

GlobeNewsWire • Mar 27, 2026

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations

GlobeNewsWire • Mar 12, 2026

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the  first quarter of 2026 -- Significant progress in next-generation PI3Kα  pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provided in 2026 BOULDER, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the third quarter ended September 30, 2025 and provided a business update.

GlobeNewsWire • Nov 6, 2025

OnKure Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:

GlobeNewsWire • Nov 4, 2025

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $83.4M expected to provide cash runway into Q4 2026 BOULDER, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.

GlobeNewsWire • Aug 12, 2025

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data

GlobeNewsWire • May 6, 2025

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024

GlobeNewsWire • Mar 10, 2025

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D.

GlobeNewsWire • Mar 4, 2025

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported

GlobeNewsWire • Dec 10, 2024